Exogenous EPO therapy has shown particular promise as a neuroprotective agent in neonates affected by Hypoxic Ischemic Encephalopathy (HIE), a hypoxic brain insult that occurs at or around the time of birth and is associated with significant neurodevelopmental morbidity11–17. Here, EPO is linked to perinatal asphyxia.